Latest Content


Excellos™ 360: Smart Starting Material Selection for Better Cells and Better Therapies 

Are you looking to optimize effective starting materials, equipment/protocol selection?
9th Jun 2023
June 29, 2023

Eureka Therapeutics Awarded $10.6M CIRM Grant for T-Cell Therapy in Pediatric Liver Cancer

Eureka Therapeutics has received a $10.6 million grant from the California Institute for Regenerative Medicine (CIRM) to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of refractory/relapsed liver cancer for pediatric patients.
8th Jun 2023

Cell and Gene Therapy Catapult Open New Edinburgh, UK, Facilities

UK-based independent innovation and technology organization Cell and Gene Therapy Catapult (CGT Catapult), has officially opened new laboratories and offices in Edinburgh, Scotland, UK, BioQuarter – enhancing Edinburgh’s role as a hub for cell therapies.
7th Jun 2023

AAV Gene Therapy Analytical Tools: Ensure Comparability and Perform Proper Safety & Efficacy Evaluations

Join the discussion uncovering the advantages of AAV analytics when using the right in-process controls and standards to ensure comparability and perform proper safety & efficacy evaluations
6th Jun 2023
Thursday, June 1, 2023 | 11:00 [EDT] | 08:00 [PDT] | 16:00 [BST]

BioCentriq® Unveils LEAP™ Advanced Therapy Platform, Enabling Rapid Patient Access for Early-Stage Biotech Companies

BioCentriq launched their new LEAP™ Advanced Therapy Platform at the 29th International Society for Cell & Gene Therapy (ISCT) annual event with proven assets and expertise to help early-stage biotech companies effectively deliver to patients without compromising quality.
5th Jun 2023

Nexcella Initiates NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Facility

Nexcella, a subsidiary of Immix Biopharma, Inc., announced the start of CAR-T NXC-201 Engineering batches at its U.S. Manufacturing site.
2nd Jun 2023

Don’t Miss Out on Our Next Webinar

Upcoming Event

Up Next: Predict & Prevent: Driving Efficiencies in CGT Manufacturing with Digitization and Partner-in-Plant Collaborations 

Join the discussion employing digital solutions to monitor, track and mitigate challenges during advanced therapy manufacturing.
15 Jun 2023
Thursday, June 15, 2023 | 11:00 [EDT] | 08:00 [PDT] | 16:00 [BST]

Access Our Webinar Library

Our eBooks & Infographics
As manufacturing pipelines scale in line with increased demand for advanced therapies, there is further demand for digital solutions to support complex manufacturing process development.
This Case Study demonstrates how the Association for the Advancement of Blood & Biotherapeutics (AABB) evaluated the apparent challenges in identifying and retaining employees due to a shortage in the worldwide biotherapies workforce.
Gene-edited cell therapies represent a rapidly growing area for advanced therapeutic development, but manufacturing-related challenges remain to commercialize such complex therapies.
This Case Study demonstrates how the Excellos team successfully carried out process development of a scale up procedure from tissue culture stacks to a commercial bioreactor system.
This Case Study demonstrates how the use of Akadeum’s microbubble platform offers a simple and highly tunable isolation and activation workflow that generates T cells ready for suspended cell culture and downstream applications, such as genetic modification and expansion, and discusses the potential impact of the solution on cancer treatment. 
What are the steps on the long and winding road from the lab bench to the clinic for a novel gene therapy?
The Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for gene therapy development.
In this infographic, we have detailed some key considerations when choosing your plasmids for CAR-T development.
As we celebrate 10 years of CAR-T, the Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for CAR-T development.
Gaining market and patient access in Europe has presented many cell and gene therapy companies with barriers. The advanced therapies industry is currently facing a dilemma: scientific advancement is exceeding market and reimbursement adaptation.